Printer Friendly

ALPHA 1 BIOMEDICALS RECEIVES THE FIRST COMMERCIAL ORDER FOR THYMOSIN ALPHA 1

 ALPHA 1 BIOMEDICALS RECEIVES THE
 FIRST COMMERCIAL ORDER FOR THYMOSIN ALPHA 1
 NEW YORK, Feb. 10 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) has received a $1,000,000 order for Thymosin alpha 1 from its Italian licensee, Sclavo, S.p.A. Sclavo filed for approval to market Thymosin alpha 1 with the Italian Ministry of Health in July 1991 and expects a decision by mid-1992.
 Dr. Vincent F. Simmon, president and chief executive officer of Alpha 1 Biomedicals, stated: "This is a major step for Alpha 1 Biomedicals. We are beginning the process of changing from a development stage company into an operating company. Under the arrangement with Sclavo, Alpha 1 Biomedicals will manufacture and supply bulk thymosin and will receive manufacturing revenues and profits as well as royalties on product sales. The current order will be filled from our existing facility and we are making plans to expand the company's manufacturing capacity to accommodate future production needs."
 The original agreement between the two companies has been modified to extend Sclavo's territory beyond Italy into Spain and Portugal and to permit Sclavo to sublicense Thymosin alpha 1 within its territory.
 Alpha 1 Biomedicals, Inc. is a Washington-based company engaged in the development of pharmaceutical products for the treatment of human immune disorders.
 -0- 2/10/92
 /CONTACT: Judith A. Hautala of Alpha 1 Biomedicals, 202-628-9898, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM) CO: Alpha 1 Biomedicals, Inc.; Sclavo, S.p.A. ST: District of Columbia IN: MTC SU:


JT-OS -- NY018 -- 8139 02/10/92 09:11 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:264
Previous Article:MGI PHARMA SUSPENDS MGI 136 CLINICAL STUDIES
Next Article:IMCO RECYCLING REPORTS FLAT 1991 EARNINGS, EXPECTS STRONG IMPROVEMENT IN 1992
Topics:


Related Articles
ALPHA 1 BIOMEDICALS COMPLETES ACQUISITION OF U.S. RIGHTS TO THYMOSIN ALPHA 1 FROM HOFFMANN-LA ROCHE
FIRST REGULATORY APPROVAL FOR THYMOSIN ALPHA 1
NEW AIDS DRUG STUDY ANNOUNCED; STANFORD RESEARCHERS TO STUDY THYMOSIN alpha I
THYMOSIN ALPHA 1 TO BE EVALUATED IN CLINICAL TRIAL IN MEXICO
ALPHA 1 BIOMEDICALS ANNOUNCES INITIATION OF ARBITRATION PROCEEDINGS WITH LICENSEE
ALPHA 1 BIOMEDICALS ANNOUNCES MANUFACTURING AGREEMENT FOR THYMOSIN ALPHA 1
ALPHA 1 BIOMEDICALS, INC., ANNOUNCES LAWSUIT BY SCICLONE PHARMACEUTICALS, INC.
SCICLONE PHARMACEUTICALS RECEIVES APPROVAL TO MARKET ZADAXIN(TM) IN SINGAPORE
ALPHA 1'S SUPPLIER EXPERIENCES MANUFACTURING DIFFICULTIES
SciClone Pharmaceuticals Receives Approval to Market ZADAXIN(R) Thymosin Alpha 1 in the People's Republic of China for the Treatment of Hepatitis B

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters